Apexigen Announces First Preclinical Data Presentations On Novel Anti-TNFR2 And Anti-SIRPa Antibody Programs At The 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN CARLOS, Calif., Nov. 9, 2020 /PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced two upcoming poster presentations at the 35(th) Society for Immunotherapy of Cancer (SITC) Annual Meeting, to be held November 9-14, 2020. Details are as follows:
Title of Presentation: APX601, A Novel TNFR2 Antagonist Antibody for Cancer Immunotherapy (Abstract ID 693)
AUTHORS: Erin L. Filbert, Sushma Krishnan, Ryan Alvarado, George Huang, Frances R. Bahjat, and Xiaodong Yang
PRESENTER: Erin L. Filbert, Ph.D.
The presenting author will answer questions on Wednesday, November 11 from 5:15 to 5:45 p.m. EST and Friday, November 13 from 4:40 to 5:10 p.m. EST.
Title of Presentation: Novel Anti-SIRP- Antibodies with Differentiated Characteristics as Promising Cancer Therapeutics (Abstract ID 188)
AUTHORS: Minu K. Srivastava, Ryan Alvarado, Sushma Krishnan, Christine Tan, Swati Jalgaonkar, George Huang, Erin L. Filbert, Frances R. Bahjat and Xiaodong Yang
PRESENTER: Erin L. Filbert, Ph.D.
The presenting author will answer questions on Thursday, November 12 from 4:50 to 5:20 p.m. EST and Saturday, November 14 from 1:00 to 1:30 p.m. EST.
The posters will be available in the Virtual Poster Hall on November 11-14, 2020, from 9:00 a.m.-5:00 p.m. EST.
About Apexigen
Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that may harness the patient's immune system to combat and eradicate cancer. APX005M, APX601 and Apexigen's other programs were discovered using Apexigen's proprietary APXiMAB(TM) discovery platform. This platform has enabled Apexigen and its various licensees to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Seven product or product candidates discovered using APXiMAB(TM) are currently commercially available or in clinical development, either internally by Apexigen or by its licensees. For more information, please visit www.apexigen.com.
Investor Contact:
Jennifer Porcelli
Managing Director
Solebury Trout
646-378-2962
investors@apexigen.com
Apexigen Contact:
Mark Nevins
Sr. Vice President, Business Development
Apexigen
650-931-6236
mnevins@apexigen.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/apexigen-announces-first-preclinical-data-presentations-on-novel-anti-tnfr2-and-anti-sirp-antibody-programs-at-the-2020-society-for-immunotherapy-of-cancer-sitc-annual-meeting-301168237.html
SOURCE Apexigen, Inc.
